Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 5/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222284 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL30731286 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| Hydrogen Sulfide SCHEMBL28270010 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| Sulfamide SCHEMBL28719576 | 0.85 | HTT (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL28130845 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6517140 | 0.81 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| Biphenyl SCHEMBL28350717 | 0.80 | NPC1 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| Sulfanilamide SCHEMBL27528584 | 0.74 | CYP2C9 (0.55) | SMN1; SMN2ALDH1A1HTTTDP1KDM4E | |
| SCHEMBL28249610 | 0.73 | CYP2C9 (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| Quinoxaline SCHEMBL27732326 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021151974-A1 | INTERFERING WITH MRNA SPLICING TO ENHANCE RESPONSE TO CHECKPOINT IMMUNOTHERAPIES. | STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2021-08-05 | — | — | WO | disclosed |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10610516-B2 | Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione | AMGEN INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3478321-A1 | PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES | Oncorus, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190000804-A1 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | AMGEN INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2018006005-A1 | PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES | ONCORUS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3258913-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF | Mallinckrodt Nuclear Medicine LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3164420-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016134066-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF | MALLINCKRODT LLC (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016004043-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | BLEND THERAPEUTICS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2014161037-A1 | ANTIBODIES AGAINST HUMAN RYK AND USES THEREFOR | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000804-A1 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | PDE4A, PDE2A, PDE4B | SMN1; SMN2 2524/4885NPC1 887/4885RAB9A 3428/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | SMN1; SMN2 4291/4885NPC1 4497/4885RAB9A 2430/4885 |
| US-10610516-B2 | Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione | PDE4A, PDE2A, PDE4B | SMN1; SMN2 2524/4885NPC1 887/4885RAB9A 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.